Analyst Ami Fadia of Needham reiterated a Buy rating on Immuneering, retaining the price target of $11.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ami Fadia has given his Buy rating due to a combination of factors tied to Immuneering’s advancing pipeline and upcoming catalysts. She highlights that the key atebimetinib plus mGnP regimen in first-line pancreatic cancer remains on schedule, with an expanded dataset including survival outcomes from more than fifty patients expected in the first half of 2026, which could be a meaningful value driver.
In addition, she notes that initiation of the Phase 3 MAPKeeper 301 trial in metastatic first-line pancreatic cancer is planned for mid-2026 after regulatory alignment in both the U.S. and Europe, and that a Phase 2 trial of atebimetinib with Libtayo in RAS‑mutant first-line NSCLC should start in the second half of 2026. Combined with a cash position of $217M at year‑end 2025, which she believes funds operations into 2029, these elements underpin her constructive outlook and support the Buy recommendation.
In another report released on March 7, TipRanks – Google also reiterated a Buy rating on the stock with a $6.00 price target.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMRX in relation to earlier this year.